标题
Pushing estrogen receptor around in breast cancer
作者
关键词
-
出版物
ENDOCRINE-RELATED CANCER
Volume 23, Issue 12, Pages T227-T241
出版商
Bioscientifica
发表日期
2016-10-12
DOI
10.1530/erc-16-0427
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial:
- (2016) J Baselga et al. CANCER RESEARCH
- Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor–Positive Breast Cancer
- (2016) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Cooperative Dynamics of AR and ER Activity in Breast Cancer
- (2016) N. C. D'Amato et al. MOLECULAR CANCER RESEARCH
- Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
- (2016) Jill M. Spoerke et al. Nature Communications
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer
- (2016) Sarat Chandarlapaty et al. JAMA Oncology
- Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer
- (2015) J. O'Shaughnessy et al. ANNALS OF ONCOLOGY
- St. Gallen endocrine response classes predict recurrence rates over time
- (2015) R.H.T. Koornstra et al. BREAST
- Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival
- (2015) Beth Overmoyer et al. CANCER RESEARCH
- The intracrinology of breast cancer
- (2015) Keely May McNamara et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Progesterone receptor modulates ERα action in breast cancer
- (2015) Hisham Mohammed et al. NATURE
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the Androgen Receptor in Breast Cancer
- (2015) KeeMing Chia et al. Current Oncology Reports
- DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
- (2015) Andrew Stone et al. Nature Communications
- 10P * A PHASE 1 OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ENZALUTAMIDE ALONE OR COMBINED WITH AN AROMATASE INHIBITOR IN WOMEN WITH ADVANCED BREAST CANCER
- (2014) T. A. Traina et al. ANNALS OF ONCOLOGY
- Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial†
- (2014) J. Bines et al. ANNALS OF ONCOLOGY
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight
- (2014) Suzanne A. W. Fuqua et al. BREAST CANCER RESEARCH AND TREATMENT
- AR collaborates with ERα in aromatase inhibitor-resistant breast cancer
- (2014) Yassine Rechoum et al. BREAST CANCER RESEARCH AND TREATMENT
- Complexities of androgen receptor signalling in breast cancer
- (2014) Keely M McNamara et al. ENDOCRINE-RELATED CANCER
- Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma
- (2014) Rika Fujii et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer
- (2014) Christopher C. Coss et al. STEROIDS
- Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
- (2013) W. Jonat et al. ANNALS OF ONCOLOGY
- A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer
- (2013) R. Charles Coombes et al. BREAST CANCER RESEARCH AND TREATMENT
- Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study
- (2013) C A Purdie et al. BRITISH JOURNAL OF CANCER
- Expression of androgen receptor and its phosphorylated forms in breast cancer progression
- (2013) Qinghu Ren et al. CANCER
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers
- (2013) Isabell Witzel et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys
- (2013) Masuo Yamaoka et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- An International Ki67 Reproducibility Study
- (2013) Mei-Yin C. Polley et al. JNCI-Journal of the National Cancer Institute
- Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
- (2013) Adrian S Dobs et al. LANCET ONCOLOGY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Reduced Androgen Receptor Expression Accelerates the Onset of ERBB2 Induced Breast Tumors in Female Mice
- (2013) Myles C. Hodgson et al. PLoS One
- Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor
- (2013) Hisham Mohammed et al. Cell Reports
- Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation
- (2012) Matthew J. Sikora et al. BREAST CANCER RESEARCH AND TREATMENT
- Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study
- (2012) John F. R. Robertson et al. BREAST CANCER RESEARCH AND TREATMENT
- Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures
- (2012) Peter Kabos et al. BREAST CANCER RESEARCH AND TREATMENT
- AIB1:ER Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor-Resistant Breast Cancer Cells
- (2012) J. O'Hara et al. CLINICAL CANCER RESEARCH
- An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity
- (2012) Nicole L Moore et al. ENDOCRINE-RELATED CANCER
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
- (2012) Masuo Yamaoka et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?
- (2012) T. E. Hickey et al. MOLECULAR ENDOCRINOLOGY
- Whole-genome analysis informs breast cancer response to aromatase inhibition
- (2012) Matthew J. Ellis et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
- (2012) Rita S. Mehta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy
- (2012) Naoko Honma et al. Breast Cancer
- Androgen Resistance in Female Mice Increases Susceptibility to DMBA-Induced Mammary Tumors
- (2012) Ulla Simanainen et al. Hormones & Cancer
- Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
- (2011) Tomohiro Kaku et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
- (2011) Sibylle Loibl et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
- (2011) Min Ni et al. CANCER CELL
- Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
- (2011) R. Hu et al. CLINICAL CANCER RESEARCH
- Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1
- (2011) Jessica L L Robinson et al. EMBO JOURNAL
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- Differential Effects of Exogenous Androgen and an Androgen Receptor Antagonist in the Peri- and Postpubertal Murine Mammary Gland
- (2011) A. A. Peters et al. ENDOCRINOLOGY
- Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer
- (2011) Carlo Palmieri et al. Expert Review of Anticancer Therapy
- Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy
- (2011) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Single-Injection Depot Progesterone Before Surgery and Survival in Women With Operable Breast Cancer: A Randomized Controlled Trial
- (2011) Rajendra Badwe et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
- (2011) Jack Cuzick et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
- (2011) Laura C Collins et al. MODERN PATHOLOGY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
- (2011) James T. Dalton et al. Journal of Cachexia Sarcopenia and Muscle
- Expression of androgen receptor in breast cancer and its significance as a prognostic factor
- (2010) Q. Yu et al. ANNALS OF ONCOLOGY
- Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers
- (2010) Isabella Castellano et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.
- (2010) E Mrozek et al. CANCER RESEARCH
- FOXA1 is a key determinant of estrogen receptor function and endocrine response
- (2010) Antoni Hurtado et al. NATURE GENETICS
- Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers
- (2010) Donata Micello et al. VIRCHOWS ARCHIV
- Additive endocrine therapy for advanced breast cancer – back to the future
- (2009) Per Eystein Lønning ACTA ONCOLOGICA
- Expression of androgen receptors in primary breast cancer
- (2009) S. Park et al. ANNALS OF ONCOLOGY
- Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations
- (2009) C. Schneider et al. CLIMACTERIC
- Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
- (2009) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit
- (2009) Michael L. Mohler et al. JOURNAL OF MEDICINAL CHEMISTRY
- Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
- (2009) Leo A Niemeier et al. MODERN PATHOLOGY
- Structural basis for androgen specificity and oestrogen synthesis in human aromatase
- (2009) Debashis Ghosh et al. NATURE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)
- (2008) Jørn Andersen et al. ACTA ONCOLOGICA
- The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance
- (2008) Matthew J. Sikora et al. BREAST CANCER RESEARCH AND TREATMENT
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
- (2008) LANCET ONCOLOGY
- Steroidal Androgens and Nonsteroidal, Tissue-Selective Androgen Receptor Modulator, S-22, Regulate Androgen Receptor Function through Distinct Genomic and Nongenomic Signaling Pathways
- (2008) Ramesh Narayanan et al. MOLECULAR ENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search